$261 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 60 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Sell | CELGENE CORP | $21,654,000 | +2.9% | 174,022 | -4.2% | 8.29% | -12.6% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $15,111,000 | -7.7% | 124,641 | -6.9% | 5.78% | -21.6% |
| SHPG | Sell | SHIRE PLCsponsored adr | $11,882,000 | -26.7% | 68,200 | -28.4% | 4.55% | -37.8% |
| AMGN | Sell | AMGEN INC | $11,010,000 | -6.0% | 67,104 | -16.2% | 4.21% | -20.1% |
| GILD | Sell | GILEAD SCIENCES INC | $6,912,000 | -45.1% | 101,784 | -42.1% | 2.65% | -53.3% |
| ENTL | Sell | ENTELLUS MED INC | $4,702,000 | -38.4% | 341,468 | -15.3% | 1.80% | -47.6% |
| TSRO | Sell | TESARO INC | $3,616,000 | -71.5% | 23,500 | -75.1% | 1.38% | -75.8% |
| EXEL | Sell | EXELIXIS INC | $2,837,000 | +2.9% | 131,000 | -29.2% | 1.09% | -12.6% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $1,707,000 | +17.3% | 49,651 | -1.6% | 0.65% | -0.3% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $1,273,000 | -61.8% | 20,000 | -73.3% | 0.49% | -67.6% |
| ICPT | Sell | INTERCEPT PHARMACEUTICALS IN | $1,262,000 | -60.7% | 11,155 | -62.3% | 0.48% | -66.6% |
| LGND | Sell | LIGAND PHARMACEUTICALS INC | $952,000 | -68.8% | 9,000 | -70.0% | 0.36% | -73.5% |
| AERI | Sell | AERIE PHARMACEUTICALS INC | $680,000 | -86.9% | 15,000 | -89.1% | 0.26% | -88.9% |
| ALDR | Sell | ALDER BIOPHARMACEUTICALS INC | $498,000 | -70.1% | 24,000 | -70.0% | 0.19% | -74.5% |
| XNCR | Sell | XENCOR INC | $430,000 | -66.0% | 18,000 | -62.5% | 0.16% | -71.0% |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -55,000 | -100.0% | -0.12% | – |
| ADAP | Exit | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $0 | – | -96,419 | -100.0% | -0.17% | – |
| ACOR | Exit | ACORDA THERAPEUTICS INC | $0 | – | -22,000 | -100.0% | -0.19% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -21,000 | -100.0% | -0.26% | – |
| ARIA | Exit | ARIAD PHARMACEUTICALS INC | $0 | – | -657,912 | -100.0% | -3.69% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-03-02
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.